← Back to Home

Swedish Orphan Biovitrum

Nasdaq Stockholm: SOBI ↗$460.00 SEK~$10B (Nasdaq Stockholm) MCAP
#Rare Hematology (Hemophilia)#Immunology#Specialty Care#Inflammation#Genetic Diseases

Swedish Orphan Biovitrum (Sobi) is a global specialty biopharmaceutical company focused on rare diseases, with a portfolio spanning hematology, immunology, and specialty care. The company markets hemophilia treatments (Eloctate, Alprolix), immunology products (Kineret, Gamifant), and specialty therapeutics, and is expanding its rare-disease pipeline through both internal R&D and acquisitions.

Company Info

Sector:Pharmaceutical / Rare Disease
Headquarters:Stockholm, Sweden
Founded:1939
Website:www.sobi.com/en

Upcoming Milestones & Key Dates

Q3 2026
Earnings

H1 2026 earnings and pipeline update

2026
Regulatory

Continued regulatory and commercial progress on gout combination drug following CRL

Clinical Development Pipeline

Kineret (anakinra)

Target: IL-1 receptor antagonist
CAPS, rheumatoid arthritis, Still's disease; expansion indications under evaluation
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Gamifant (emapalumab)

Target: Anti-IFNγ monoclonal antibody
Primary hemophagocytic lymphohistiocytosis (HLH); expansion to additional inflammatory indications
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Doptelet (avatrombopag)

Target: Thrombopoietin receptor agonist
Chronic immune thrombocytopenia (ITP); chronic liver disease-associated thrombocytopenia
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Guido Oelkers

Chief Executive Officer

Henrik Stenlund

Chief Financial Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →